Drug Type Gene therapy |
Synonyms LentiGlobin BB305, lovo-cel + [1] |
Target |
Action stimulants |
Mechanism β-globin stimulants(Hemoglobin beta chain stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (08 Dec 2023), |
Regulation- |
Start Date21 Oct 2020 |
Sponsor / Collaborator |
Start Date14 Feb 2020 |
Sponsor / Collaborator |
Start Date02 Feb 2015 |
Sponsor / Collaborator |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Sickle Cell | United States | 08 Dec 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Chest Syndrome | Phase 2 | United States | 02 Feb 2015 | |
Anemia, Sickle Cell | Preclinical | France | 07 Jun 2013 | |
Beta-Thalassemia | Preclinical | France | 07 Jun 2013 | |
Transfusion-dependent Beta Thalassemia | Preclinical | France | 07 Jun 2013 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1/2 | 47 | Lovotibeglogene Autotemcel (Lovo-cel) (Lovo-cel) | (jtanngxcqp) = wpzxmtxhtn toyqwqnjmh (lklcaqijfc ) View more | Positive | 01 Feb 2024 | ||
Phase 1/2 | 7 | (LentiGlobin BB305 Drug Product for SCD) | qiptxpjhuh(qotpaodort) = qzocxeznmo ikpcvyuebq (svvruayqzr, wkybasykhv - xmdjhztcnz) View more | - | 10 Mar 2020 | ||
(LentiGlobin BB305 Drug Product for TDT) | qiptxpjhuh(qotpaodort) = pthqxhiaav ikpcvyuebq (svvruayqzr, amutnvwjuw - hwwgwikzzx) View more |